Compare ALB & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALB | INCY |
|---|---|---|
| Founded | 1994 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8B | 17.0B |
| IPO Year | 1995 | 1994 |
| Metric | ALB | INCY |
|---|---|---|
| Price | $134.65 | $128.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 21 |
| Target Price | ★ $179.74 | $103.52 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | 48.57 | ★ 4173.33 |
| EPS | ★ 5.87 | 1.47 |
| Revenue | ★ $5,142,733,000.00 | $3,394,635,000.00 |
| Revenue This Year | $12.12 | $10.44 |
| Revenue Next Year | $5.74 | $10.99 |
| P/E Ratio | ★ $22.91 | $87.16 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $71.25 | $81.09 |
| 52 Week High | $221.00 | $132.60 |
| Indicator | ALB | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 60.23 |
| Support Level | $117.61 | $98.50 |
| Resistance Level | $183.34 | $132.60 |
| Average True Range (ATR) | 4.65 | 2.81 |
| MACD | 1.26 | 0.20 |
| Stochastic Oscillator | 48.17 | 71.00 |
Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.